Table 2 Supporting evidence of druggable genes

From: Mendelian randomization and colocalization analysis reveal novel drug targets for myasthenia gravis

Gene	Disease	eQTL	Heterogeneity	Pleiotropy	Direction	Colocalization	pQTL
CDC42BPB	MG MG (Late-onset)	√ √	√ √	√ √	√ √	√ √	× ×
CD226	MG MG (Late-onset)	√ √	√ √	√ √	√ √	√ √	×/√ ×/√
TNFSF12	MG MG (Late-onset)	√ √	√ √	√ √	√ √	√ √	√ √
KAT2B	MG	√	√	√	√	×
LEAP2	MG	√	√	√	√	×
THRA	MG	√	√	√	√	×	×
PRSS36	MG	√	√		√	√
CORIN	MG (Early-onset)	√	√	√	√	×
TNFSF13	MG (Late-onset)	√	√	√	√	×	×
CFD	MG (Late-onset)	√	√	√	√	×	×
KLRD1	MG (Late-onset)	√	√	√	√	×	×
LMCD1	MG (Late-onset)	√	√	√	√	×

√ pass, × fail, blank not possible to test, ×/√ pass in some datasets, eQTL expression quantitative trait locus, pQTL protein quantitative trait locus
Additional supporting information can be found online at the end of the article

Back to article page

ISSN: 1479-7364

Contact us

General enquiries: journalsubmissions@springernature.com